The presence of intracellular prodrug activation was confirmed by the capacity of the internalized P-Dex to inhibit TNFα and IL-6 release from LPS-treated macrophages and to reduce expression of MMP1 and MMP3 in RA synovial fibroblasts. The gene discussed is IL6; the disease is rheumatoid arthritis.